D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 118.5 SEK 3.04% Market Closed
Market Cap: 2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Devyser Diagnostics AB
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Change in Working Capital
-kr30.9m
CAGR 3-Years
-208%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Change in Working Capital
-kr40.9m
CAGR 3-Years
-20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Change in Working Capital
-kr160.9m
CAGR 3-Years
-123%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Change in Working Capital
-kr332m
CAGR 3-Years
-70%
CAGR 5-Years
-17%
CAGR 10-Years
-37%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Change in Working Capital
-kr3.2B
CAGR 3-Years
-11%
CAGR 5-Years
-35%
CAGR 10-Years
-50%
BioArctic AB
STO:BIOA B
Change in Working Capital
kr47.2m
CAGR 3-Years
55%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
118.6 SEK
Fairly Valued
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Change in Working Capital?
Change in Working Capital
-30.9m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Change in Working Capital amounts to -30.9m SEK.

What is Devyser Diagnostics AB's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-208%

The average annual Change in Working Capital growth rates for Devyser Diagnostics AB have been -208% over the past three years .

Back to Top